[go: up one dir, main page]

CN1022323C - 从外消旋体中分离咪唑衍生物的d-对映体的方法 - Google Patents

从外消旋体中分离咪唑衍生物的d-对映体的方法 Download PDF

Info

Publication number
CN1022323C
CN1022323C CN88104440A CN88104440A CN1022323C CN 1022323 C CN1022323 C CN 1022323C CN 88104440 A CN88104440 A CN 88104440A CN 88104440 A CN88104440 A CN 88104440A CN 1022323 C CN1022323 C CN 1022323C
Authority
CN
China
Prior art keywords
enantiomorph
medetomidine
mixture
gaonist
separating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN88104440A
Other languages
English (en)
Other versions
CN1030576A (zh
Inventor
阿托·约翰内斯·卡雅赖伦
赖莫·艾那里·弗尔坦伦
艾诺·予汉尼萨沃赖伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Farmos Yhtyma Oy
Original Assignee
Farmos Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10620775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1022323(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmos Yhtyma Oy filed Critical Farmos Yhtyma Oy
Publication of CN1030576A publication Critical patent/CN1030576A/zh
Application granted granted Critical
Publication of CN1022323C publication Critical patent/CN1022323C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Optical Record Carriers And Manufacture Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

分离得到Medetomidine的d和1对映体以及它们的盐是有选择性的和有效的α-受体促效药。

Description

本发明涉及将咪唑衍生物从相应的外消旋混合物中分离的方法。
4-[1-（2，3-二甲基苯基）乙基]-1H-咪唑，亦称作medetomidine具有下式结构，并被认为是有选择性的和有效的α2-受体促效药，它已被揭示，如在欧洲专利公开号72615中作为抗高血压剂和在欧洲专利公开号187471中作为兽医的镇静止痛剂。
Figure 881044407_IMG1
Medetomidine的旋光性d-和e-对映体和它们无毒的药物上可接受的酸加成盐是新的化合物。这些化合物可以通过下式来表示：
Figure 881044407_IMG2
按照本发明的特点，通过将该外消旋体先转化成非对映异构体混合物，再用分级结晶法将混合物分离而从medetomidine中分离出d-对映体。由于Medetomidine是碱，因此它可以通过与旋光性酸如酒石酸反应转化成非对映异构体盐混合物。其它有用的旋光性酸例如为（-）-苹果酸，（-）-扁挑酸和（+）-樟脑-10-磺酸，（+）-酒石酸对于拆开外消旋混合物是特别有用的。非对映体的分离是通过从醇例如甲醇或乙醇或它们的混合物中重复结晶来完成的。
在分离非对映体后，该酸加成盐能反转为游离碱，即通过用氢氧化钠制得它碱性水溶液，再用合适的有机溶剂如二氯甲烷萃取已释放的碱。
Medetomidine的d-和l-对映体与有机酸或无机酸反应形成相应的酸加成盐，该盐具有与碱相同的治疗效能，因此它们能形成药物上有效的酸加成盐，例如：氯化物、溴化物、硫酸盐、硝酸盐、磷酸盐、磺酸盐、甲酸盐、酒石酸盐、马来酸盐、枸椽酸盐、萃甲酸盐、水杨酸盐和抗坏血酸盐等。
Medetomidine的d-和l-对映体是有选择性的和有效的α2-受体促效药。
肾上腺素能受体是生理上的重要结合部位，它对去甲肾上腺素和肾上腺素有特异性，它位于细胞膜表面。交感神经系统的肾上腺素能受体分成两类不同的亚型，α-受体和β-受体，它们又进一步划分为两亚组，即是α1和α2以及β1和β2受体。在这些受体类型中，β1、β2和α1主要位于例如平滑肌表面突触后部位并因此传递如平滑肌的收缩或舒张;而α2-受体主要位于去甲肾上腺素能神经末端的突触前部位。如果在生理条件下用去甲肾上腺素刺激α2-受体，则中断了肾上腺素的释放，也就是说这是一种负反馈现象这种负反馈现象还可以通过某些合成的α2-促效药象Medetomidine和某些它的近似衍生物来诱发。
在动物实验中，证明了本发明的d-和l-对映体并尤其是d-对映体同外消旋混合物（即Medetomidine）相比较具有高度增强α2-的选择性以及具有更高的效力。d-对映体作为如镇静一止痛、抗忧虑或抗高血压剂的价值是能预期的。另外，在α2-肾上腺受体的生理学和药理学的研究中，d-对映体能用作为药理学工具。
本发明化合物的药理学活性测定如下：
1.在体外的α2-促药效性
通过分离，电刺激老鼠输精管制品来测定α2-促药效性（Marshallet al.，Br.J.Pharmac.62，147，151，1978）。在这个试验物中，α2-促效药可以通过激活突触前α2-肾上腺受体的来阻断因电诱导的平滑肌收缩，并因此减少运动传递质的分泌。已知的α2-促效药如detomidine，Medetomidine和可乐宁是用作参照物。实验结果示于表1，在表中，α2-促效药的作用是用pD2-值表示（即产生最大抑制的50%的试验化合物摩尔浓度的负对 数）。（表1见文后）
这些结果表明Medetomidine的α2-促效药活性限于d-对映体。同其它研究的试剂相比较表明d-对映体增强α2-促效药活性。
2.在体外α2/α1的选择性
用大鼠的脑膜通过受体结合实验来研究作为α2-促效药的d-对映体选择性。正如Virtanen和Nyman在Eur.J.Pharmac.108，163-9，1985上揭示的那样，d-异构体和这些参照化合物对于同3H-可乐宁（用于α2-受体）和3H-吡唑嗪（用于α1-受体）的竞争能力已作了基本研究、试验结果示于表2，在表中，研究试剂对于同3H-可乐宁和3H-吡唑嗪的结合竞争能力用IC50-值表示（即为对于替换50%放射活性配位体所需的竞争配位体的摩尔浓度）。（表2见文后）
上述结果表明d-对映体同Meaetomidine和其它参照化合物比较是一个最有选择性的α2-促效药。
3.镇静止痛作用
通过用小鼠的自发能动性和因剧痛翻试验来研究本发明化合物镇静止痛性能。用Animex活性测定仪测定小鼠和大鼠的自发能动性。在2分钟测定周期前30分钟，试验化合物经腹膜注射给药。
在剧痛翻滚试验中，将研究化合物和食盐水以同样情况给大鼠皮下用药，过45分钟后腹膜注射给于1ml1%乙酸，接着在25分钟时间记录翻滚的数目（Kosler    et    al.，Fred.Proc，18：412，1959）。
结果示于表3和表4。
表3：研究化合物在减低小鼠自发能动性的ED50值。（表3见文后）
表4：研究化合物在小鼠以乙酸诱发剧痛翻滚试验中的ED值。（表4见文后）
这些结果表明d-对映体同外消旋混合物（Medetomidine）和其它参照化合物相比较有增强镇静止痛的性能。Medetomidine的镇静止痛作用局限于d-对映体。
4.抗忧虑作用
使用Handley和Mithoni在Naunyn-Schmiedeb，Arch，Pharmacol.237，1-5    1984叙述的方法研究本发明化合物的抗忧虑作用。在本试验中，测定大鼠在升高的t-迷宫中对开口的和闭合的通道的探索方式。表明抗忧虑药增加了对与开口通道相关的探索。在t-迷宫的中央放置一个老鼠并于5分钟内记录老鼠进入开口和闭合通道的次数，得到的结果示于表5。（见文后）
上述结果表明d-对映体在升高的t-迷宫试验中有抗忧虑的表现。
众所周知对于病症断除的连贯忧虑状态是由于去甲肾上腺素能的机能亢进。因此，用例如可乐宁药物降低去甲肾上腺素的水平，能成功地治疗这些病症。在大鼠实验中表明d-对映体能减抄去甲肾上腺素的释放并因此在中枢神经系统和周围神经系统调和交感神经。通过给大鼠施用d-对映体后，测定MHPG-SO4的CSF浓度（中枢神经去甲肾上腺素的主要代谢产物）已经清楚地证明了上述观点。该结果示于表6。（见文后）
5.抗高血压作用
本发明化合物的抗高血压性能研究如下：
将标准体重的Sprague-Dawly大鼠首先用氨基甲酸乙酯麻醉，然后将股动脉用聚乙烯管连接到血压传感器上，再将试验物注射入股静脉，用记录器自动记录血压和脉博频率，结果示于表7。（见文后）
表7：在麻醉大鼠中d-对映体的抗高血压作用结果表明d-对映体具有明显的抗高血压和心动徐缓作用。
因此d-和l-对映体及它们的无毒性的药物上可接受的酸加成盐或它们的混合物可以肠胃外、静脉注射或口服给药。一般，将有效量的本发明化合物与合适的药物载体结合使用。按本文使用的术语“有效量”是指包括那些能产生所需要的活性但不会发生有害付作用的量。在特定场合时使用的正确量取决于许多因素如：给药方法，哺乳动物种类，为施用本发明衍生物的条件等，自然也取决于衍生物的结构。
同本发明化合物一起使用的具有代表性的药物载体可以是固体或液体，通常以按照愿望给药的具体安排方式来选择。这样，固体载体的实例包括乳糖、蔗糖、明胶和琼脂，液体载体的实例包括水、糖浆、花生油和橄榄油。其它合适的载体是在药剂配方领域中那些技术人员所公知的。本发明的衍生物和载体相结合可以制成许多可接受的形式如：片剂、胶囊、栓剂、溶液、乳剂和粉剂。
以下实例说明本发明新的对映体的制备。
实例
Medetomidine（碱）14g溶于50ml甲醇，10.5g（+）-酒石酸溶于50ml甲醇，将两种溶液混合后，蒸发溶剂至体积为50ml，混合物注入冰浴中得到9g白色沉淀。将沉淀悬浮于25ml乙醇中，混合物置于超声波中14分钟然后过滤，用蒸汽浴加热将沉淀溶于20ml无水乙醇和60ml甲醇的混合物，冷却后得到5g沉淀（旋光度+55°），用60ml甲醇重结晶后得到4.1g产品，旋光度+60°。将产品进行反复重结晶直至旋光度不再增加为止。d-对映体酒石酸盐溶于水中，将溶液配制成硷性，d-对映体溶于有机溶剂如二氯甲烷或乙醚。d-对映体碱的旋光度为+75°。
d-对映体可以从母液中分离得到。
表1
化合物 α2-促效药在体外（老鼠输精管）的pD2
d-对映体    9.3
l-对映体    6.0（部分促药效）
Medetomidine    9.0
detomidine    8.5
可乐宁    8.5
表2
化合物3H-可乐宁3H-吡唑嗪 α2/α1-选择性
替换IC50，nM 替换IC50，nM
d-对映体    1.2    55019    45849
l-对映体    46    189975    4129
Medetomidine    3.3    16700    5060
Detomidine    3.7    242    65
可乐宁    6.4    6200    969
表3
化合物 ED50（mg/kg s.c）
d-对映体    0.02
l-对映体    ＞10
Medetomidine    0.05
Detomidine    0.3
可乐宁    0.3
表4
化合物 ED50（mg/kg s.c）
d-对映体    0.01
l-对映体    ＞10
Medetomidine    0.02
Detomidine    0.02
可乐宁    0.03
表5
药物/剂量，    进入平均数（n＝6）
mg/kg    开口    闭合    总数    开口/总数
NaCl    3.4    8.6    12.0    0.28
d-对映体
0.0003    4.8    10.6    14.0    0.20
0.001    3.2    10.6    13.8    0.23
0.003    4.0    9.5    13.5    0.29
0.01    5.8    8.8    14.6    0.39
0.03    2.5    3.0    5.5    0.45
安定
1    5.2    10.5    15.7    0.33
表6
d-对映体剂量μg/kg CSFMHPG-SO4（%对照）
（在施用d-对映体4小时后）
0    100
3    -10
10    -20
30    -30
100    -65
表7
剂量mg/kg    血压下降%    心率下降%
0.001    -8    -21
0.002    -23    -40
0.01    -43    -47
0.03    -45    -48
0.1    -45    -50

Claims (2)

1、一种从外消旋的4-[1-(2，3-二甲基苯基)乙基]-1H-咪唑分离4-[1-(2，3-二甲基苯基)乙基]-1H-咪唑d-对映体的方法，该方法包括通过与旋光性酸反应使外消旋的4-[1-(2，3-二甲基苯基)乙基]-1H-咪唑转化成非对映异构体的盐混合物，然后用分级结晶的分法分离该非对映异构体盐的混合物。
2、按照权利要求1的方法，其中使用的旋光性酸是（+）-酒石酸。
CN88104440A 1987-07-16 1988-07-16 从外消旋体中分离咪唑衍生物的d-对映体的方法 Expired - Lifetime CN1022323C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8716803 1987-07-16
GB8716803A GB2206880B (en) 1987-07-16 1987-07-16 Optical isomers of an imidazole derivative

Publications (2)

Publication Number Publication Date
CN1030576A CN1030576A (zh) 1989-01-25
CN1022323C true CN1022323C (zh) 1993-10-06

Family

ID=10620775

Family Applications (1)

Application Number Title Priority Date Filing Date
CN88104440A Expired - Lifetime CN1022323C (zh) 1987-07-16 1988-07-16 从外消旋体中分离咪唑衍生物的d-对映体的方法

Country Status (29)

Country Link
US (1) US4910214A (zh)
EP (1) EP0300652B1 (zh)
JP (1) JPH0625138B2 (zh)
KR (1) KR940007311B1 (zh)
CN (1) CN1022323C (zh)
AT (1) ATE71941T1 (zh)
AU (1) AU600839B2 (zh)
BG (1) BG60473B2 (zh)
CA (1) CA1337659C (zh)
CY (2) CY1787A (zh)
DD (1) DD281807A5 (zh)
DE (2) DE3867945D1 (zh)
DK (1) DK165788C (zh)
ES (1) ES2038757T3 (zh)
FI (1) FI95375C (zh)
GB (1) GB2206880B (zh)
GR (1) GR3003878T3 (zh)
HK (1) HK56094A (zh)
HU (1) HU198693B (zh)
IE (1) IE60456B1 (zh)
IL (1) IL87076A0 (zh)
LU (1) LU91010I2 (zh)
NL (1) NL300117I2 (zh)
NO (2) NO170579C (zh)
NZ (1) NZ225362A (zh)
PT (1) PT88013B (zh)
SU (1) SU1648248A3 (zh)
UA (1) UA5560A1 (zh)
ZA (1) ZA885134B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
CN105175339A (zh) * 2015-10-09 2015-12-23 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2215206B (en) * 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
GB2281206A (en) * 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
IN187238B (zh) * 1995-06-30 2002-03-09 Astra Ab
GB9521680D0 (en) * 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
NZ518447A (en) 1999-10-29 2004-10-29 Orion Corp Treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
ATE536867T1 (de) 2006-03-16 2011-12-15 Tris Pharma Inc Modifizierte freisetzungsformulierungen mit arznei-ion-austausch-harzkomplexen
US7795263B2 (en) * 2008-07-08 2010-09-14 Wildlife Laboratories, Inc. Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) * 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
KR101859486B1 (ko) * 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
CN101671305A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 一种拆分美托咪定的左旋及右旋对映体的方法
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
WO2013069025A1 (en) 2011-11-11 2013-05-16 Neon Laboratories Ltd. "process for the preparation of dexmedetomidine"
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
ITMI20120311A1 (it) * 2012-02-29 2013-08-30 Edmond Pharma Srl Procedimento per la risoluzione di medetomidina e recupero dell'enantiomero indesiderato
BR112015003120B1 (pt) 2012-08-15 2022-08-09 Tris Pharma , Inc Tablete mastigável de liberação estendida de metilfenidato e seu uso
HUE037272T2 (hu) * 2012-10-15 2018-08-28 Orion Corp Állatorvosi módszer zajérzékenység enyhítésére
RU2646512C2 (ru) 2013-10-07 2018-03-05 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Устройства для трансдермальной доставки дексмедетомидина и способы их применения
RU2648449C2 (ru) 2013-10-07 2018-03-26 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы и композиции для трансдермальной доставки неседативного количества дексмедетомидина
KR101831290B1 (ko) 2013-10-07 2018-02-22 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 조성물을 사용하여 주의력 결핍 과잉행동 장애, 불안 및 불면증을 치료하기 위한 방법 및 조성물
US9717796B1 (en) 2016-04-20 2017-08-01 Slypharma, Llc Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container
FR3054218B1 (fr) * 2016-07-22 2020-03-06 Universite De Rouen Procede de dedoublement de sels de baclofene
RU2723761C1 (ru) 2016-10-31 2020-06-17 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Способы устранения боли с использованием устройств для трансдермальной доставки дексмедетомидина
US11160791B2 (en) 2018-11-01 2021-11-02 Medefil, Inc. Dexmedetomidine injection premix formulation in ready to use (RTU) bags
CN115197149B (zh) * 2021-04-02 2023-09-22 四川大学华西医院 一种5-苄基咪唑类化合物及其制备方法和用途
CN114671811A (zh) * 2022-04-14 2022-06-28 南京正科医药股份有限公司 一种右美托咪定拆分副产物的外消旋化回收方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU518569B2 (en) * 1979-08-07 1981-10-08 Farmos-Yhtyma Oy 4-benzyl- and 4-benzoyl imidazole derivatives
GB2092569B (en) * 1981-02-05 1984-09-19 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
DE3531682A1 (de) * 1985-09-05 1987-03-12 Thomae Gmbh Dr K (+)-6-chlor-5,10-dihydro-5-((1-methyl-4- piperidinyl)acetyl)-11h-dibenzo(b,e)(1,4) diazepin-11-on, seine isolierung und verwendung als arzneimittel

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464619A (zh) * 2010-11-17 2012-05-23 桑迪亚医药技术（上海）有限责任公司 一种左旋4-[1-(2,3-二甲基苯基)乙基]-1r-咪唑消旋化方法
CN105175339A (zh) * 2015-10-09 2015-12-23 辰欣药业股份有限公司 一种制备盐酸右美托咪定的方法

Also Published As

Publication number Publication date
ES2038757T3 (es) 1993-08-01
IE60456B1 (en) 1994-07-13
KR890002030A (ko) 1989-04-07
FI95375B (fi) 1995-10-13
HU198693B (en) 1989-11-28
DE10399005I2 (de) 2012-06-06
AU600839B2 (en) 1990-08-23
AU1894188A (en) 1989-01-19
GB2206880A (en) 1989-01-18
FI95375C (fi) 1996-01-25
FI882819A0 (fi) 1988-06-14
EP0300652B1 (en) 1992-01-22
DD281807A5 (de) 1990-08-22
DE10399005I1 (de) 2003-06-05
FI882819L (fi) 1989-01-17
ZA885134B (en) 1989-04-26
JPH0625138B2 (ja) 1994-04-06
SU1648248A3 (ru) 1991-05-07
CA1337659C (en) 1995-11-28
CY1787A (en) 1995-10-20
NO883155L (no) 1989-01-17
NZ225362A (en) 1990-07-26
CN1030576A (zh) 1989-01-25
GR3003878T3 (zh) 1993-03-16
NL300117I1 (nl) 2003-05-01
US4910214A (en) 1990-03-20
JPS6434968A (en) 1989-02-06
UA5560A1 (uk) 1994-12-28
NO2003004I2 (no) 2005-03-21
DE3867945D1 (de) 1992-03-05
DK386288D0 (da) 1988-07-11
IL87076A0 (en) 1988-12-30
HUT48218A (en) 1989-05-29
DK386288A (da) 1989-01-17
KR940007311B1 (ko) 1994-08-12
EP0300652A1 (en) 1989-01-25
NO170579B (no) 1992-07-27
NL300117I2 (nl) 2003-10-01
GB2206880B (en) 1991-04-24
DK165788B (da) 1993-01-18
GB8716803D0 (en) 1987-08-19
PT88013B (pt) 1995-03-01
CY2004006I2 (el) 2009-11-04
CY2004006I1 (el) 2009-11-04
BG60473B2 (bg) 1995-04-28
IE882174L (en) 1989-01-16
LU91010I2 (fr) 2003-06-19
ATE71941T1 (de) 1992-02-15
DK165788C (da) 1993-06-14
PT88013A (pt) 1989-06-30
NO883155D0 (no) 1988-07-15
NO170579C (no) 1992-11-04
HK56094A (en) 1994-06-03

Similar Documents

Publication Publication Date Title
CN1022323C (zh) 从外消旋体中分离咪唑衍生物的d-对映体的方法
CZ149898A3 (cs) Použití epinastinu pro výrobu farmaceutického prostředku
CN1087340A (zh) 哌啶衍生物及其制备和在治疗学上的应用
CN1454054A (zh) 用(r)－奥昔布宁和(r)－去乙基奥昔布宁治疗平滑肌机能亢进
CN1324239A (zh) 镇痛剂
CN1226175A (zh) 吸收促进剂
CN1085979C (zh) 麻药型镇痛剂依赖性/抗性形成抑制剂
CN1077790C (zh) 青光眼治疗剂及眼压降低剂
US20200215068A1 (en) Treatment of type i and type ii diabetes
CN1249682A (zh) 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
AU2001256685A1 (en) Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions
EP1315488A2 (en) Pharmaceutical compositions containing aminothiazole derivatives for the treatment of colonic motor dysfunctions
CN1498109A (zh) 膀胱感觉过敏治疗剂
JP2012513443A5 (zh)
CN1276753C (zh) 用于治疗类阿片依赖性的吡啶－2－基－甲胺衍生物
CN1290581C (zh) 高血压症治疗药
CN1048381A (zh) [α-(叔丁基氨基甲基)-3，4-二氯苄基]硫代乙酰胺，其制备方法及应用
CN1699370A (zh) 青蒿琥酯盐及其制备方法和应用
CN1708308A (zh) 福辛普利降低透析患者心血管事件的用途
KR820001304B1 (ko) 펜아탄올아민의 제조방법
CN1589154A (zh) 含有血管紧张肽ii受体拮抗剂的药用组合物
EP0473285A1 (en) Use of 2-(phenoxypropanolamino)ethoxyphenoxyacetic acid and its derivatives to inhibit gastrointestinal motility
KR820001303B1 (ko) 펜에탄올아민의 제조방법
CN1274581A (zh) α－肾上腺素受体阻断剂在制备治疗男性性功能障碍之药物中的应用
JPH039105B2 (zh)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C17 Cessation of patent right
CX01 Expiry of patent term